Hot Flashes and Related Outcomes in Breast Cancer Survivors and Matched Comparison Women

Janet S. Carpenter

David H. Johnson

Lois J. Wagner

Michael A. Andrykowski

ONF 2002, 29(3), E16-E25. DOI: 10.1188/02.ONF.E16-E25

Purpose/Objectives: To compare the hot flash symptom experience and related outcomes between breast cancer survivors and healthy women.

Design: Descriptive, cross-sectional, comparative study.

Setting: Southeastern university medical center.

Sample: 69 of 207 breast cancer survivors contacted via a tumor registry and 63 age-matched healthy female volunteers. Survivors were a mean of 57 years and a mean of 39 months postdiagnosis.

Methods: Mailed survey included a demographic, disease, and treatment information form; a gynecologic history form; a two-day, prospective, hot flash diary; a detailed hot flash questionnaire; mood and affect scales; and the Hot Flash-Related Daily Interference Scale.

Main Research Variables: Hot flashes, mood, affect, interference with daily activities, and overall quality of life.

Findings: Breast cancer survivors had hot flashes that were significantly more frequent, severe, distressing, and of greater duration. Breast cancer survivors were less likely to be using hormone replacement and more likely to have tried nonhormonal prescription interventions in the past, but reported significantly less effectiveness from hot flash treatments. Breast cancer survivors with severe hot flashes reported significantly greater mood disturbance; higher negative affect; more interference with daily activities, including sleep, concentration, and sexuality; and poorer overall quality of life in comparison to breast cancer survivors with no hot flashes to mild hot flashes. Hot flash quality and triggers were not significantly different between groups. No clear temporal pattern of hot flashes emerged.

Conclusions: Hot flashes are a significant problem for breast cancer survivors, even for those who are naturally postmenopausal (i.e., did not undergo menopause as a result of surgery or the effects of chemotherapy). Hot flashes remained fairly stable over time and did not diminish in frequency, severity, or associated distress.

Implications for Nursing: The findings guide the assessment of the uniqueness of the problem of hot flashes experienced by breast cancer survivors and help define outcomes to address in clinical practice or include in future hot flash intervention research.

Jump to a section


    Avis, N.E., Brambilla, D., McKinlay, S.M., & Vass, K. (1994). A longitudinal analysis of the association between menopause and depression: Results of the Massachusetts women's health study. Annals of Epidemiology, 4, 214--220.

    Barton, D.L., Loprinzi, C.L., Quella, S.K., Sloan, J.A., Veeder, M.H., Egner, J.R., et al. (1998). Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. Journal of Clinical Oncology, 16, 495--500.

    Bartsch, C., Bartsch, H., Fuchs, U., Lippert, T.H., Bellman, O., & Gutpa, D. (1989). Stage-dependent depression of melatonin in patients with primary breast cancer: Correlation with prolactin, thyroid stimulating hormone, and steroid receptors. Cancer, 64, 426--433.

    Brambilla, D.J., McKinlay, S.M., & Johannes, C.B. (1994). Defining the perimenopause for application in epidemiologic investigations. American Journal of Epidemiology, 140, 1091--1095.

    Brzezinski, A. (1995). Management of menopause in women with breast cancer. Israel Journal of Medical Science, 3, 163--168.

    Burger, H.G. (1994). The menopause: When it is all over or is it? Australian New Zealand Journal of Obstetrics and Gynecology, 34, 293--295.

    Carpenter, J.S. (2000). Hot flashes and their management in breast cancer. Seminars in Oncology Nursing, 16, 214--225.

    Carpenter, J.S. (2001). The hot flash-related daily interference scale: A tool for assessing the impact of hot flashes on quality of life following breast cancer. Journal of Pain and Symptom Management, 22, 979--989.

    Carpenter, J.S., & Andrykowski, M.A. (1999). Menopausal symptoms in breast cancer survivors. Oncology Nursing Forum, 26, 1311--1317.

    Carpenter, J.S., Andrykowski, M.A., Freedman, R.R., & Munn, R. (1999). Feasibility and psychometrics of an ambulatory hot flash monitoring device. Menopause: The Journal of the American Menopause Society, 6, 209--215.

    Carpenter, J.S., Andrykowski, M.A., Studts, J.L., Cordova, M.J., Cunningham, L., McGrath, P.C., et al. (1998). Hot flashes in postmenopausal women treated for breast cancer: Prevalence, severity, correlates, management, and relation to quality of life. Cancer, 82, 1682--1691.

    Carpenter, J.S., Gautam, S., Andrykowski, M., & Freedman, R.R. (2001). Circadian rhythm of objectively recorded hot flashes in postmenopausal breast cancer survivors. Menopause, 8, 181--188.

    Couzi, R.J., Helzlsouer, K.J., & Fetting, J.H. (1995). Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. Journal of Clinical Oncology, 13, 2737--2744.

    Curran, S.L., Andrykowski, M.A., & Studts, J.L. (1995). Short form of the Profile of Mood States (POMS-SF): Psychometric information. Psychological Assessment, 7(1), 80--83.

    Daut, R.L., Cleeland, C.S., & Flanery, R.C. (1983). Development of the Wisconsin Brief Pain Inventory to assess pain in cancer and other diseases. Pain, 17, 197--210.

    Dennerstein, L., Smith, A.M., Morse, C., Burger, H., Green, A., Hopper, J., et al. (1993). Menopausal symptoms in Australian women. Medical Journal of Australia, 159, 232--236.

    Dodd, M.J., Miaskowski, C., & Paul, S.M. (2001). Symptom clusters and their effect on the functional status of patients with cancer. Oncology Nursing Forum, 28, 465--470.

    Finck, G., Barton, D.L., Loprinzi, C.L., Quella, S.K., & Sloan, J.A. (1998). Definitions of hot flashes in breast cancer survivors. Journal of Pain and Symptom Management, 16, 327--333.

    Freedman, R.R. (1989). Laboratory and ambulatory monitoring or menopausal hot flashes. Psychophysiology, 26, 573--579.

    Goldberg, R.M., Loprinzi, C.L., O'Fallon, J.R., Veeder, M.H., Miser, A.W., Maillard, J.A., et al. (1994). Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. Journal of Clinical Oncology, 12, 155--158.

    Greene, R.A. (2000). Cerebral blood flow. Fertility and Sterility, 73, 143.

    Hann, D., Winter, K., & Jacobsen, P. (1999). Measurement of depressive symptoms in cancer patients: Evaluation of the Center for Epidemiological Studies Depression Scale (CES-D). Journal of Psychosomatic Research, 46, 437--443.

    Ivarsson, T., Spetz, A.C., & Hammar, M. (1998). Physical exercise and vasomotor symptoms in postmenopausal women. Maturitas, 29, 139--146.

    Koller, M., Kussman, J., Lorenz, W., Jenkins, M., Voss, M., Arens, E., et al. (1996). Symptom reporting in cancer patients: The role of negative affect and experienced social stigma. Cancer, 77, 983--995.

    Koster, A. (1991). Change-of-life anticipations, attitudes, and experiences among middle-aged Danish women. Health Care for Women International, 12(1), 1--13.

    Kostoglou-Athanassiou, I., Ntalles, K., Gogas, J., Markopoulos, C., Alevizou-Terzaki, V., Athanassiou, P., et al. (1995). Sex hormones in postmenopausal women with breast cancer on tamoxifen. Hormone Research, 47, 116--120.

    Kronenberg, F. (1990). Hot flashes: Epidemiology and physiology. Annals of the New York Academy of Sciences, 592, 52--86.

    Kronenberg, F. (1994). Hot flashes: Phenomenology, quality of life, and search for treatment options. Experimental Gerontology, 29, 319--336.

    Loprinzi, C.L., Michalak, J.C., Quella, S.K., O'Fallon, J.R., Hatfield, A.K., Nelimark, R.A., et al. (1994). Megestrol acetate for the prevention of hot flashes. New England Journal of Medicine, 33, 347--352.

    Loprinzi, C.L., Pisansky, T.M., Foneseca, R., Sloan, J.A., Zahasky, K.M., Quella, S.K., et al. (1998). Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. Journal of Clinical Oncology, 16, 2377--2381.

    Love, R.R. (1989). Tamoxifen therapy in primary breast cancer: Biology, efficacy, and side effects. Journal of Clinical Oncology, 7, 803--815.

    Love, R.R., Cameron, L., Connell, B.L., & Levanthal, H. (1991). Symptoms associated with tamoxifen treatment in postmenopausal women. Archives of Internal Medicine, 151, 1842--1847.

    Lum, S.S., Woltering, E.A., Fletcher, W.S., & Pommier, R.F. (1997). Changes in serum estrogen levels in women during tamoxifen therapy. American Journal of Surgery, 173, 399--402.

    Matthews, K.A. (1992). Myths and realities of the menopause. Psychosomatic Medicine, 54, 1--9.

    Mayer, D.K., & Linscott, E. (1995). Information for women: Management of menopausal symptoms. Oncology Nursing Forum, 22, 1567--1570.

    McNair, P.M., Lorr, M., & Droppelman, L. (1981). POMS manual (2nd ed.). San Diego: Educational and Testing Service.

    Miller, K.L. (1992). Alternatives to estrogen for menopausal symptoms. Clinical Obstetrics and Gynecology, 35, 884--893.

    Mormont, M.C., & Levi, F. (1997). Circadian-system alterations during cancer processes: A review. International Journal of Cancer, 70, 241--247.

    Pasacreta, J.V., & McCorkle, R. (1998). Providing accurate information to women about tamoxifen therapy for breast cancer: Current indications, effects, and controversies. Oncology Nursing Forum, 25, 1577--1583.

    Quella, S., Loprinzi, C.L., Sloan, J., Vaught, N., Dekrey, W., Fischer, T., et al. (1998). Long-term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer, 82, 1784--1788.

    Reichman, B.S., & Green, K.B. (1994). Breast cancer in young women: Effect of chemotherapy on ovarian function, fertility, and birth defects. Journal of the National Cancer Institute Monographs, 16, 125--129.

    Runowicz, C.D. (1996). Hormone replacement therapy in cancer survivors: A con opinion. CA: Cancer Journal for Clinicians, 46, 365--373.

    Shacham, S. (1983). A shortened version of the Profile of Mood States. Journal of Personality Assessment, 47, 305--306.

    Stellato, R.K., Crawford, S.L., McKinlay, S.M., & Longcope, C. (1998). Can follicle-stimulating hormone be used to define menopausal status? Endocrine Practice, 4, 137--141.

    Swam, S., Santen, R., Burger, H., & Pritchard, K. (1999). Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 4: Urogenital atrophy, vasomotor instability, sleep disorders, and related symptoms. Oncology, 13, 551--575.

    University of California, San Francisco School of Nursing Symptom Management Faculty Group. (1994). A model for symptom management. Image: Journal of Nursing Scholarship, 26, 272--276.

    Watson, D., Clark, L.A., & Tellegen, A. (1998). Development and validation of brief measures of positive and negative affect: The PANAS scales. Journal of Personality and Social Psychology, 54, 1063--1070.

    Watson, D., & Pennebaker, J.W. (1989). Health complaints, stress, and distress: Exploring the central role of negative affectivity. Psychological Review, 96, 234--254.